Novo Nordisk’s Pill Breakthrough Meets a Cybersecurity Reality Check
The same week that brought Novo Nordisk a historic regulatory green light for its oral weight-loss pill also…
Novo Nordisk’s European Breakthrough Tempered by Growing Generics Threat in Brazil and Beyond
France will publicly reimburse Wegovy and Mounjaro, and EMA backs new oral and high-dose versions, but Brazil’s first…
Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow
Novo Nordisk’s stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift…
Novo Nordisk’s Teen Pill Breakthrough and Canadian Generic Blow Arrive in the Same Week
Novo Nordisk faces a historic Ozempic generic in Canada while scoring a first-in-class oral GLP-1 win for teens,…
Novo Nordisk’s Buyback and Breakthrough Paint a Complex Picture
Novo Nordisk executes major share buybacks and announces positive Phase 3 results for sickle cell drug etavopivat, pressuring…
Novo Nordisk’s Rare Disease Breakthrough Fails to Lift Oversold Shares
Novo Nordisk reports positive Phase 3 results for sickle cell drug etavopivat, but shares remain under pressure from…
Novo Nordisk’s Blood Disorder Breakthrough Offers a Lifeline Amid GLP-1 Gloom
Novo Nordisk’s etavopivat succeeds in Phase 3 sickle cell trial, cutting painful crises by 27%. This diversifies its…
Novo Nordisk’s European Logistics Breakthrough Meets US Pricing Headwinds
EMA relaxes Wegovy cold-chain rules, cutting EU distribution costs. Novo faces 2026 sales decline from US pricing pressure…